Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry

JACC: Heart Failure

Volumn 8, Issue 6, 2020, Pages 469-480

  Vaduganathan, Muthiah ^a   Fonarow, Gregg C ^b   Greene, Stephen J ^c   DeVore, Adam D ^c   Kavati, Abhishek ^d   Sikirica, Slaven ^d   Albert, Nancy M ^e   Duffy, Carol I ^d   Hill, C Larry ^c   Patterson, J Herbert ^f   Spertus, John A ^g   Thomas, Laine E ^c   Williams, Fredonia B ^h   Hernandez, Adrian F ^c   Butler, Javed ⁱ  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e LERNER RESEARCH INSTITUTE   (United States)

^f University of North Carolina   (United States)

^g SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^h Mended Hearts   (United States)

ⁱ UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

clinical outcomes; diabetes mellitus; guideline directed medical therapy; heart failure

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENKEPHALINASE INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INSULIN; METFORMIN; MINERALOCORTICOID ANTAGONIST; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; BODY MASS; COMORBIDITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEMOGRAPHY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART FAILURE WITH REDUCED EJECTION FRACTION; HOSPITALIZATION; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEW YORK HEART ASSOCIATION CLASS; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; TELEPHONE INTERVIEW; HEART FAILURE; HEART STROKE VOLUME; MIDDLE AGED; OUTPATIENT; PATHOPHYSIOLOGY; PHYSIOLOGY; PROTOCOL COMPLIANCE; REGISTER; TIME FACTOR; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COMORBIDITY; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; GUIDELINE ADHERENCE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; MINERALOCORTICOID RECEPTOR ANTAGONISTS; OUTPATIENTS; PROSPECTIVE STUDIES; REGISTRIES; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME;

EID: 85084740707     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2019.12.015     Document Type: Article

References (40)

1. Seferovic, J.P., Claggett, B., Seidelmann, S.B., et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol 5 (2017), 333–340.
2. McMurray, J.J.V., DeMets, D.L., Inzucchi, S.E., et al. The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. Eur J Heart Fail 21 (2019), 1402–1411.
3. Gregg, E.W., Hora, I., Benoit, S.R., Resurgence in diabetes-related complications. JAMA 321 (2019), 1867–1868.
4. Greene, S.J., Vaduganathan, M., Khan, M.S., et al. Prevalent and incident heart failure in cardiovascular outcome trials of patients with type 2 diabetes. J Am Coll Cardiol 71 (2018), 1379–1390.
5. McMurray, J.J., Gerstein, H.C., Holman, R.R., Pfeffer, M.A., Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2 (2014), 843–851.
6. Rawshani, A., Rawshani, A., Franzen, S., et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 379 (2018), 633–644.
7. Kelly, T.N., Bazzano, L.A., Fonseca, V.A., Thethi, T.K., Reynolds, K., He, J., Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 151 (2009), 394–403.
8. White, W.B., Kupfer, S., Zannad, F., et al. Cardiovascular mortality in patients with type 2 diabetes and recent acute coronary syndromes from the EXAMINE trial. Diabetes Care 39 (2016), 1267–1273.
9. DeVore, A.D., Thomas, L., Albert, N.M., et al. Change the management of patients with heart failure: rationale and design of the CHAMP-HF registry. Am Heart J 189 (2017), 177–183.
10. Hamby, R.I., Zoneraich, S., Sherman, L., Diabetic cardiomyopathy. JAMA 229 (1974), 1749–1754.
11. Rubler, S., Dlugash, J., Yuceoglu, Y.Z., Kumral, T., Branwood, A.W., Grishman, A., New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30 (1972), 595–602.
12. Butler, J., Yang, M., Manzi, M.A., et al. Clinical course of patients with worsening heart failure with reduced ejection fraction. J Am Coll Cardiol 73 (2019), 935–944.
13. Hernandez, A.V., Usmani, A., Rajamanickam, A., Moheet, A., Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta–analysis and meta-regression analysis of placebo-controlled randomized clinical trials. Am J Cardiovasc Drugs 11 (2011), 115–128.
14. Scirica, B.M., Bhatt, D.L., Braunwald, E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369 (2013), 1317–1326.
15. Zannad, F., Cannon, C.P., Cushman, W.C., et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385 (2015), 2067–2076.
16. Zelniker, T.A., Wiviott, S.D., Raz, I., et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393 (2019), 31–39.
17. McMurray, J.J.V., Solomon, S.D., Inzucchi, S.E., et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381 (2019), 1995–2008.
18. Kristensen, S.L., Rorth, R., Jhund, P.S., et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7 (2019), 776–785.
19. Margulies, K.B., Hernandez, A.F., Redfield, M.M., et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 316 (2016), 500–508.
20. Jorsal, A., Kistorp, C., Holmager, P., et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 19 (2017), 69–77.
21. Hernandez, A.F., Green, J.B., Janmohamed, S., et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392 (2018), 1519–1529.
22. Fudim, M., White, J., Pagidipati, N.J., et al. Effect of once-weekly exenatide in patients with type 2 diabetes with and without heart failure and heart failure-related outcomes: insights from the EXSCEL trial. Circulation 140 (2019), 1613–1622.
23. Greene, S.J., Butler, J., Albert, N.M., et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol 72 (2018), 351–366.
24. Greene, S.J., Fonarow, G.C., DeVore, A.D., et al. Titration of medical therapy for heart failure with reduced ejection fraction. J Am Coll Cardiol 73 (2019), 2365–2383.
25. Arnold, S.V., Inzucchi, S.E., McGuire, D.K., et al. Evaluating the quality of comprehensive cardiometabolic care for patients with type 2 diabetes in the U.S.: the diabetes collaborative registry. Diabetes Care 39 (2016), e99–e101.
26. Arnold, S.V., Inzucchi, S.E., Tang, F., et al. Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: an NCDR research to practice project. Eur J Prev Cardiol 24 (2017), 1637–1645.
27. Arnold, S.V., de Lemos, J.A., Rosenson, R.S., et al. Use of guideline-recommended risk-reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease: insights from Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD). Circulation 140 (2019), 618–620.
28. Vaduganathan, M., Sathiyakumar, V., Singh, A., et al. Prescriber patterns of SGLT2i after expansions of U.S. Food and Drug Administration labeling. J Am Coll Cardiol 72 (2018), 3370–3372.
29. Vaduganathan, M., Patel, R.B., Singh, A., et al. Prescription of glucagon-like peptide-1 receptor agonists by cardiologists. J Am Coll Cardiol 73 (2019), 1596–1598.
30. Vardeny, O., Vaduganathan, M., Practical guide to prescribing sodium-glucose cotransporter 2 inhibitors for cardiologists. J Am Coll Cardiol HF 7 (2019), 169–172.
31. Goldenberg, R.M., Berard, L.D., Cheng, A.Y.Y., et al. SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther 38 (2016), 2654–2664.
32. Peters, A.L., Buschur, E.O., Buse, J.B., Cohan, P., Diner, J.C., Hirsch, I.B., Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 38 (2015), 1687–1693.
33. Bhagat, A.A., Greene, S.J., Vaduganathan, M., Fonarow, G.C., Butler, J., Initiation, continuation, switching, and withdrawal of heart failure medical therapies during hospitalization. J Am Coll Cardiol HF 7 (2019), 1–12.
34. Bailey, C.J., Under-treatment of type 2 diabetes: causes and outcomes of clinical inertia. Int J Clin Pract 70 (2016), 988–995.
35. Reach, G., Pechtner, V., Gentilella, R., Corcos, A., Ceriello, A., Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab 43 (2017), 501–511.
36. Thomas, M., Khariton, Y., Fonarow, G.C., et al. Association of changes in heart failure treatment with patients' health status: real-world evidence from CHAMP-HF. J Am Coll Cardiol HF 7 (2019), 615–625.
37. Cosentino, F., Grant, P.J., Aboyans, V., et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 41 (2020), 255–323.
38. Sumarsono, A., Everett, B.M., McGuire, D.K., et al. Trends in aggregate use and associated expenditures of antihyperglycemic therapies among U.S. Medicare beneficiaries between 2012 and 2017. JAMA Intern Med 180 (2019), 141–144.
39. DeJong, C., Kazi, D.S., Dudley, R.A., Chen, R., Tseng, C.-W., Assessment of national coverage and out-of-pocket costs for sacubitril/valsartan under Medicare part D assessment of national coverage and out-of-pocket costs for sacubitril/valsartan under Medicare part D. JAMA Cardiology 4 (2019), 828–830.
40. Smith, G.H., Shore, S., Allen, L.A., et al. Discussing Out-of-Pocket Costs With Patients: Shared Decision Making for Sacubitril-Valsartan in Heart Failure. J Am Heart Assoc, 8, 2019, e010635.